Executive Team

Steven B. Engle
Chairman of the Board of Directors and Chief Executive Officer

Patrick J. Scannon, M.D., Ph.D.
Executive Vice President and Chief Medical Officer

Fred Kurland
Vice President, Finance and Chief Financial Officer

Daniel P. Cafaro
Vice President, Regulatory Affairs and Compliance

Stephen K. Doberstein, Ph.D.
Vice President of Research

Christopher J. Margolin
Vice President, General Counsel and Secretary

Calvin L. McGoogan
Vice President, Quality & Facilities

Robert S. Tenerowicz
Vice President, Operations

Charles C. Wells
Vice President, Human Resources and Information Technology



Steven B. Engle

Mr. Engle was appointed chairman and chief executive officer in 2007. With more than 25 years of executive leadership and biotechnology and pharmaceutical industry experience, his expertise spans the areas of therapeutic products, operations and corporate development. He previously served as chairman of the board and chief executive officer of La Jolla Pharmaceutical Company, a publicly-held biopharmaceutical company focused on the research and development of therapeutic products for autoimmune and antibody-mediated diseases. He joined La Jolla Pharmaceutical Company in 1993, became president and a director in 1994, CEO in 1995, and chairman of the board in 1997. Prior to joining La Jolla, he held executive-level positions at Cygnus Therapeutic Systems, a developer of drug delivery systems, and Micro Power Systems, Inc., a manufacturer of high technology products, including medical devices. He began his professional career with the Strategic Decisions Group and the Stanford Research Institute. Mr. Engle is a graduate of the University of Texas with B.S. and M.S. degrees in biomedical engineering.


Patrick J. Scannon, M.D., Ph.D.

is XOMA's Company Founder, Executive Vice President, Chief Medical Officer and a member of the Board of Directors of XOMA Ltd. Since 1980, Dr. Scannon has directed the Company's product identification, evaluation and clinical testing programs. As Chief Biotechnology Officer, he heads the clinical and preclinical research programs, evaluating several classes of biologic compounds and conducting clinical studies for infectious, oncologic and immunologic indications. Dr. Scannon holds a Ph.D. in organic chemistry from the University of California, Berkeley and a medical degree from the Medical College of Georgia. He completed his medical internship and residency at the Letterman Army Medical Center in San Francisco. A board-certified internist, Dr. Scannon is also a member of the American College of Physicians. He has served as a Trustee of the University of California Berkeley Foundation and is a member of the University of California Berkeley Chancellor's Community Advisory Board. He has served or is serving on the boards of several companies and institutions, and is currently a member of the DSRC (Defense Sciences Research Council), an advisory board for DARPA (Defense Advanced Research Projects Agency) and also a member of the Department of Defense’s Threat Reduction Advisory Committee (TRAC), where he is Chair of the ChemBioWarfare Defense Panel. Dr. Scannon is inventor or co-inventor of several issued U.S. patents, and he has published numerous scientific abstracts and papers.


Fred Kurland

Fred Kurland is Vice President, Finance and Chief Financial Officer of XOMA Ltd. He is responsible for all financial matters affecting or involving the XOMA companies, including directing XOMA’s financial strategy, accounting, budgeting, financial planning and analysis and investor relations functions. Prior to joining the Company in late 2008, Mr. Kurland was Chief Financial Officer of Bayhill Therapeutics, Inc. from 2007 until late 2008. He was Chief Financial Officer of Corcept Therapeutics Incorporated from 2004 until April 2007. Mr. Kurland served as Vice President and Chief Financial Officer of Genitope Corporation from 2002 until 2004. From 1998 to 2002 he served as Senior Vice President and Chief Financial Officer of Aviron. Mr. Kurland served as Vice President and Chief Financial Officer of Protein Design Labs, Inc. from 1996 to 1998 and from 1995 to 1996 he served as Vice President, Chief Financial Officer and Secretary of Applied Immune Sciences, Inc. He held a number of financial management positions at Syntex Corporation between 1981 and 1995 including Vice President and Controller between 1991 and 1995. Mr. Kurland received his B.S. from Lehigh University and his J.D. and M.B.A. degrees from the University of Chicago.

Daniel P. Cafaro

is XOMA's Vice President, Regulatory Affairs and Compliance. Mr. Cafaro joined the Company in 1996 as Director of Regulatory Affairs. In addition to directing worldwide regulatory activities for the Company, he has had responsibility for leadership of several development programs including ophthalmic applications. From 1981 to 1996, Mr. Cafaro held several managerial positions at Allergan, Inc., directing worldwide regulatory affairs and product development. He belongs to several professional societies including the Regulatory Affairs Professional Society (RAPS), The Organisation for Professionals in Regulatory Affairs (TOPRA), and the Drug Information Association (DIA). Mr. Cafaro holds a B.S. in chemistry from the University of California Los Angeles.


Stephen K. Doberstein, Ph.D.

is Vice President of Research. Dr. Doberstein leads the Preclinical Research and Development organization at XOMA and is responsible for directing the discovery and development of XOMA's drug candidates, including antibody discovery, cell line development, and support of clinical development through non-clinical safety, translational medicine and pharmacokinetics/ pharmacodynamics. Dr. Doberstein brings 15 years of experience in biotechnology research and development. Most recently, he was Vice President, Research at Five Prime Therapeutics, Inc., a protein and antibody discovery and development company. Prior to his position at Five Prime, he served as Vice President, Research, at Xencor, Inc., an antibody engineering and development company, where he was instrumental in advancing its protein platform technologies and preclinical product candidates.

Dr. Doberstein holds a Ph.D. in Biochemistry, and Cell and Molecular Biology from Johns Hopkins University School of Medicine and completed his postdoctoral work at UC Berkeley. He began his career as an Engineer at DuPont after earning his B.S. Ch.E. degree in Chemical Engineering from the University of Delaware.


Christopher J. Margolin

is Vice President, General Counsel and Secretary of XOMA Ltd. and Secretary to the Board of Directors. He is responsible for the management of all legal matters affecting or involving the XOMA companies, including corporate governance, financings, intellectual property, licensing, litigation and mergers and acquisitions. Prior to joining the Company in 1991, Mr. Margolin was a corporate attorney holding several different positions including Assistant General Counsel at Raychem Corporation, an international high technology company, for 11 years. From 1975 to 1980, he was a division counsel for TRW and from 1972 to 1975, he was an associate at the law firm of McCutcheon, Black, Verleger and Shea in Los Angeles. A graduate of Princeton University, he holds a law degree from the University of Pennsylvania and an M.B.A. from the UCLA Graduate School of Management, and he is a member of the California and American Bar Associations.


Calvin L. McGoogan

is XOMA’s Vice President of Quality & Facilities. He joined the company in 2002 as Director of Quality Assurance. In addition to Quality Assurance, Mr. McGoogan has responsibility for the Quality Control and Quality Engineering functions at XOMA. Mr. McGoogan has over 20 years of previous Quality experience working for Dey Laboratories, International Medication Systems, and American McGaw. He is a member of the American Society for Quality, and through ASQ is a certified quality engineer, certified quality auditor, and certified quality manager. He is also a member of the Parenteral Drug Association and the International Society of Pharmaceutical Engineers. Mr. McGoogan holds a B.S. in Biology from the Florida State University, and an M.B.A. from Golden Gate University.


Robert S. Tenerowicz

is Vice President, Operations. Mr. Tenerowicz joined XOMA in December 2004 and is responsible for XOMA's operations, which include project and alliance management, process development and manufacturing, and materials management/purchasing. Before joining XOMA, Mr.Tenerowicz was vice president of manufacturing and project management at GenVec, Inc. He has been working in the biotechnology industry since 1985 and brings over 20 years of biotechnology industry and product development experience which includes his time working for GenVec, Abgenix, Cell Genesys, and Genentech. Mr. Tenerowicz holds a B.S. in physiology from the University of California at Davis and an M.B.A. in operations management from Golden Gate University and is a member of the Keck Graduate Institute’s Amgen Bioprocessing Center Advisory Board.


Charles C. Wells

is Vice President, Human Resources and Information Technology. In this role, Mr. Wells is responsible for setting and implementing company’s Human Resources and Information Technology strategies. Prior to joining XOMA in May 2001, he served as Senior Vice President, Human Resources for Roche Pharmaceuticals, a position he held since 1995. During a career that spans more than 30 years, Mr. Wells has held human resources positions with Syntex Corporation (prior to the Roche acquisition), Epic Healthcare (a hospital management company), Frito Lay and Burlington Industries. In these various roles, he has been instrumental in the design and delivery of a number of key domestic and international change initiatives and processes that brought to fruition human resource strategies developed under his leadership. Mr. Wells holds a B.A. in Psychology from Pfeiffer University in Misenheimer, North Carolina. He is a member of the Society for Human Resources Management, the Northern California Human Resource Council, and the HR Strategic Issues Council.